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Introduction
L-asparaginase (EC 3.5.1.1; L-asparagine amidohydrolase) 
an important enzyme with known antineoplastic effect 
since 19671 catalyzes the conversion of L-asparagine 
amino acid (Asn) to L-aspartic acid and ammonia.2 
This therapeutic enzyme is applied primarily for the 
management of acute lymphoblastic leukemia (ALL). 
ALL is a case of leukemia affecting mainly children, 
contributing to approximately 80% of childhood and 
20% of adult leukemias, respectively.3,4 L-asparaginase is 
found in various organisms including animals, plant cells, 
yeast, fungi, and bacteria,5 however, the bacterial enzyme 
has gained more attention in therapeutic application 
because of the higher substrate specificity and longer half-
life.1,2 Currently, Erwinia chrysanthemi and Escherichia 
coli are widely used in the pharmaceutical industry to 
produce L-asparaginase for the treatment of leukemia.6 
In the United States, 3 asparaginase formulations 
are widely used against ALL including native E. coli 
asparaginase (Elspar®), its pegylated form (Oncaspar®) 
and Erwinase from cultures of E. chrysanthemi.3 In recent 
years, the PEGylation has widely been used in order to 
improve the blood-circulation half-life, to minimize the 
immunological clearances via reticuloendothelial system 
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Abstract
Introduction: The bacterial enzyme has 
gained more attention in therapeutic 
application because of the higher 
substrate specificity and longer half-life. 
L-asparaginase is an important enzyme 
with known antineoplastic effect against 
acute lymphoblastic leukemia (ALL).
Methods: Novel L-asparaginase genes 
were identified from a locally isolated 
halo-thermotolerant Bacillus strain and the recombinant enzymes were overexpressed in modified 
E. coli strains, OrigamiTM B and BL21. In addition, the biochemical properties of the purified 
enzymes were characterized, and the enzyme activity was evaluated at different temperatures, pH, 
and substrate concentrations. 
Results: The concentration of pure soluble enzyme obtained from Origami strain was ~30 mg/L 
of bacterial culture, which indicates the significant improvement compared to L-asparaginase 
produced by E. coli BL21 strain. The catalytic activity assay on the identified L-asparaginases 
(ansA1 and ansA3 genes) from Bacillus sp. SL-1 demonstrated that only ansA1 gene codes an 
active and stable homologue (ASPase A1) with high substrate affinity toward L-asparagine. The 
Kcat and Km values for the purified ASPase A1 enzyme were 23.96s-1 and 10.66 µM, respectively. In 
addition, the recombinant ASPase A1 enzyme from Bacillus sp. SL-1 possessed higher specificity 
to L-asparagine than L-glutamine. The ASPase A1 enzyme was highly thermostable and resistant 
to the wide range of pH 4.5–10.
Conclusion: The biochemical properties of the novel ASPase A1 derived from Bacillus sp. SL-l 
indicated a great potential for the identified enzyme in pharmaceutical and industrial applications.
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for long periods of time without significant loss of 
activities. Another advantage of these enzymes is their 
typical resistance to the variable concentration of sodium 
chloride.17,18
In the current study, a new halo-thermotolerant 
Bacillus sp. SL-1, isolated from Saline Lake of Iran16 was 
investigated as the source of novel L-asparaginases.19 Two 
ansA1 and ansA3 L-asparaginase genes from Bacillus sp. 
SL-1 were cloned and overexpressed in Origami (modified 
E. coli expression strain trxB2/gor2 double mutant) and 
E. coli BL21. The biochemical properties of the purified 
enzymes were characterized, and the enzyme activity was 
evaluated at different temperatures, pH, and substrate 
concentrations. The results of the present study revealed 
that only ansA1 gene codes for a novel catalytically active 
L-asparaginase, with high catalytic activity, whereas ansA3 
gene was an inactive protein without any L-asparaginase 
activity.
Materials and Methods 
Reagents
In the present study, all of the mentioned reagents were 
analytical grade. DNA extraction kit was obtained from 
Qiagen (Germany). Other kits such as Gel extraction, 
plasmid purification, and BM chemiluminescence western 
blotting kits were purchased from Roche Company 
(Germany). Micro BCA protein assay kit was obtained 
from Thermo Scientific (USA). DNA ladders, NdeI, 
XhoI, XbaI, SalI and T4 DNA ligase were acquired from 
Fermentas (Russia). Ni Sepharose 6 Fast flow medium 
was from GE Healthcare Life Sciences (Sweden). His-Tag 
monoclonal primary antibody and goat anti-mouse IgG-
HRP conjugated secondary antibody were obtained from 
GE Healthcare and Santa Cruz companies, respectively. 
Tryptone and NaCl were from Scharlau (Barcelona, 
Spain). Finally, yeast extract, agar, and glycerol were 
provided from Applichem (Darmstadt, Germany). 
Clinically approved E. coli L-asparaginase (Leunase®) was 
purchased from Kyowa Hakko Kirin Company (Japan).
Cells and strains conditions 
According to the authors previous study,16 halo-
thermotolerant Bacillus sp. SL-1 was isolated from the 
Aran-Bidgol salt lake located in the central region of Iran. 
Later on, this strain was donated into Iranian Biological 
Resource Center (IBRC-M 11052), recognized as an 
international culture collection, and is currently available 
for all scientists and investigators. In the current study, 
all of the utilized E. coli strains (i.e., Origami, DH5α, 
and BL21) were obtained from Novagen (Darmstadt, 
Germany).
Cloning and sub-cloning of L-asparaginase genes from 
Bacillus sp. SL-1
According to the manufacturer’s instructions, QIAamp 
DNA kit (Qiagen, Germany) was utilized for Genomic 
(RES) and to maximize the intratumoral penetration and 
biodistribution of the administered drugs.7-9 The anti-
leukemia activity of L-asparaginase is due to its depleting 
effect on the concentration of Asn in the extracellular 
fluid. Unlike normal cells, tumor cells, more specifically 
leukemia cells, have little or no asparagine synthetase 
enzyme and require exogenous asparagine to keep 
their rapid malignant growth.10,11 Diminished level of 
L-asparagine and inability of leukemic cells to synthesize 
their own L-asparagine leads to the inhibition of protein 
synthesis, cell cycle arrest in the G1-phase, and ultimately 
apoptosis in susceptible leukemic cells.12 In addition, 
L-asparaginase is enzymatically active against L-glutamine 
(Gln) but with a significantly lower affinity than that for 
L-asparagine.10 This property leads to L-glutaminase 
activity associated side effects of L-asparaginase treatment. 
However, this activity contributes to the depletion of both 
Asn and Gln amino acids which have shown in some 
studies leads to the suppression of malignant cell growth 
in certain cancers.3 
Despite significant advantages of L-asparaginase 
development, clinical application of this bacterial 
enzyme is limited by immune system response and 
antibody production against foreign L-asparaginase.5,13 
Anti-asparaginase antibodies are responsible for major 
toxicity and resistance to asparaginase therapy and 
also reduce the therapeutic efficacy of asparaginase in 
some cancer cases.3 Rapid plasma clearance, shorter 
duration of activity, frequent injections to maintain the 
required therapeutic level, and development of immune 
responses, as well as the anaphylactic shock, are the main 
restrictions of current commercial L-asparaginases.3,12 
Low substrate specificity is another problem associated 
with the commercial L-asparaginases, which can cause 
liver dysfunction, pancreatitis, leucopenia, neurological 
seizures, and coagulation abnormalities leading to 
intracranial thrombosis or hemorrhage.6
It has been demonstrated that L-asparaginases derived 
from various microorganisms show different properties 
and do not share antigenic cross-reactivity. Therefore, 
when patients develop hypersensitivity to L-asparaginase 
from E. coli, enzyme from E. chrysanthemi can be replaced 
to avoid risk of allergic reactions.5,14,15 This condition 
attracted scientist for discovering this activity in many 
other microorganisms. Hence there is a request for 
the novel and robust L-asparaginase from alternative 
GRAS (generally recognized as safe) microorganisms. 
Researchers are studying new microbial sources of 
L-asparaginase which have improved stability, lower 
glutaminase activity with high substrate affinity, and 
sufficient half-life under physiological conditions.3,4 
Halo-thermotolerant or halo-thermophile organisms, 
living under extreme physicochemical conditions, are a 
valuable source of stable and resistant enzymes that can 
potentially lead to advances in biocatalysis production.16 
Thermostable enzymes can be stored at room temperature 
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DNA extraction from Bacillus sp. SL-1. The principles, 
which were followed for primer design were based on the 
high similarity of 16S rDNA sequences derived from Bacil-
lus sp. SL-1 (GenBank accession no. JQ996502) and Bacil-
lus licheniformis (strain ATCC 14580). Polymerase chain 
reactions were carried out for amplification of the L-aspar-
aginase genes (ansA1 and ansA3) by utilizing the ansA1 
forward (5′-TCTTCATATGAATAAAAAA GTAGCTCT-
CATTACAACG-3′) and ansA1 reverse (5′- AACAGTC-
GACCTAATAGCA GAATTTGTCTTTTATGCCTT-3′) 
and ansA3 forward (5′- TATACATATGAAAAAGTTAC 
TGCTGTTGACCACC-3′) and ansA3 reverse (5′- CAAG-
GTCGACTTATATGATGATATCGTCTGCAATC-3′)
(Bioron, Germany, ordered via FAZA Biotech, Iran). It 
should be noticed that the italic scripts in the primers 
are the recognition sites for NdeI and SalI endonucleases. 
Thereupon, NdeI and SalI endonucleases cleaved the PCR 
products and those products were subsequently ligated 
into the pET28a+ expression vector at 16°C overnight. 
In a process known as bacterial transformation, the pro-
duced constructs were transferred into E. coli DH5α for 
plasmid amplification and extraction by utilizing plasmid 
purification kit. Subsequently, for examining the presence 
of ansA1 and ansA3 coding sequences, the purified plas-
mid constructs had to be tested. The aforementioned ex-
amination was conducted by PCR reactions utilizing the 
previously mentioned primers and universal primers for 
the pET vectors. Additionally, XbaI and SalI endonucle-
ases were utilized in order to sub-cloning the ansA1 and 
ansA3 genes into the pET22b+ expression vector. The se-
quencing of the generated constructs are required in order 
to confirm the sequence of the ansA1 and ansA3 genes, 
therefore the accuracy of the generated constructs was 
verified by Sanger sequencing20 at Sequetech, USA.
Sequence analysis of L-asparaginase genes from Bacillus 
sp. SL-1 
After analyzing the nucleotide sequences of L-asparaginase 
genes, they were also analyzed by BLASTn database 
search method provided by NCBI (http://www.ncbi.nlm.
nih.gov). In addition, the translation tool provided by 
the ExPASy server (http://web.expasy.org/translate/) was 
utilized to translate the nucleotide sequence in order to 
obtain the amino acid sequences of Bacillus sp. SL-1 
L-asparaginases. ClustalW and Jalview programs were 
also utilized for alignment. ProtParam (http://www.
expasy.org/tools/protparam.html) was used for predicting 
the L-asparaginase related molecular mass and theoretical 
pI (isoelectric point) values.
 
Expression and extraction of recombinant L-asparaginase 
enzymes
For investigating the expression profile of the recombinant 
L-asparaginases, E. coli BL21 and Origami prokaryotic 
expression systems were utilized in aerobic condition in 
Luria-Bertani (LB) medium. The recombinant constructs 
pET22-ansA1 and pET22-ansA3 were transformed into 
chemically competent E. coli cells (BL21 and Origami). 
The transformed cells were plated on LB ampicilin plates 
and incubated at 37°C overnight. A single well isolated 
colony was used to inoculate 10 mL LB+ampicilin 
medium followed by overnight incubation at 37°C. The 
starter cultures were diluted 1:100 in fresh LB medium 
supplemented with ampicillin in the scale of 100 μg/mL 
and incubated at 37°C with shaking at 180 rpm until 
optical density of 0.6. Then, the expression was induced by 
adding isopropyl β-D-1-thiogalactopyranoside (IPTG) in 
0.4 mM and overnight incubation at 20°C with shaking at 
140 rpm. Bacterial cells were harvested by centrifugation at 
5000×g for 15 minutes. After discarding the supernatant, 
the pellet was resuspended in the lysis buffer (50 mM 
Tris-HCl pH 8, 100 mM NaCl, 1% Triton X-100, 1.4 mM 
protease inhibitor (PMSF), 0.1% β-mercaptoethanol and 
0.1 mg/mL lysozyme). For efficient disruption of the 
cells, three rounds of freezing and thawing steps were 
utilized using liquid nitrogen. Subsequently, the lysate was 
sonicated 5 times on ice at 60% amplitude for 30 seconds 
with 1 minute interval. Bacterial debris was removed by 
centrifugation at 13 000×g for 10 minutes at 4°C and then 
the soluble fraction was filtered through a 0.22 µm filter 
and subjected to purification step. 
Purification of recombinant L-asparaginase, SDS-PAGE 
and western blot analysis 
Purification of the recombinant L-asparaginase enzymes 
was performed by exploiting affinity chromatography in 
certain conditions (bath and gravity-flow conditions), as 
described previously.17 Briefly, the filtered soluble fraction 
was applied to Ni Sepharose resin pre-equilibration 
with lysis buffer and incubated at 4°C for one hour. 
After removal of the flow through, the affinity resin was 
washed (Tris 50 mM, NaCl 150 mM, β-mercaptoethanol 
0.1%, and imidazole 20 mM) three times and the bound 
6×His-tagged proteins were eluted by imidazole solution 
(imidazole 500 mM, sodium phosphate 20 mM, NaCl 500 
mM, pH 7). To remove imidazole, the purified protein 
samples were dialyzed against the buffer containing 100 
mM NaCl and 50 mM Tris-HCl adjusted at pH 8. The 
prepared purified recombinant protein concentration 
was determined by micro BCA protein assay method 
using bovine serum albumin (BSA) standard solutions 
and the obtained proteins named L-asparaginase A1 
(ASPase A1) and L-asparaginase A3 (ASPase A3). Protein 
analysis at different steps of expression and purification 
was carried out on 12% polyacrylamide gel (SDS-PAGE) 
stained by Coomassie brilliant blue G-250. Immediately 
after SDS-PAGE, the proteins were transferred onto a 
polyvinylidene fluoride (PVDF) membrane for western 
blotting. The membrane was blocked at 4°C overnight 
in 5% BSA dissolved in TBST (20 mM Tris–HCl, 
containing 150 mM NaCl and 0.05% Tween-20 at pH 7.5). 
Subsequently, the blocked membrane was incubated with 
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mouse anti-His monoclonal primary antibody (1:3,000) 
at room temperature for 1.5 hours. The membrane was 
washed three times with TBST for 5 min each at room 
temperature. Then, the membrane was incubated with 
goat anti-mouse IgG-HRP in 3% BSA at 1:8,000 dilution 
for one hour at room temperature and finally the protein 
bands were detected by chemiluminescence.
Enzyme activity assay of ASPase A1 and ASPase A3 
The enzyme activities were determined by measuring 
the released ammonia during L-asparagine hydrolysis 
using Nessler’s reagent.21 In order to reach temperature 
equilibration the reaction mixture (2 mL), consisting of 
50 mM Tris-HCl (pH 8.6) and 10 mM L-asparagine was 
incubated at 37°C for 5-6 minutes. After adding 100 µL 
diluted enzyme at zero time, the reaction proceeded at 
37°C for precisely 10 minutes and paused by adding 100 
µL of 1.5 M trichloroacetic acid (TCA) only to "Test" 
tubes. Prior to incubation, the blank tube was terminated 
by adding 100 µL of 1.5 M TCA. After centrifugation of 
the reaction mixture, 500 µL of clarified supernatant 
was mixed with 7.0 mL of ultrapure water and 1.0 mL 
of Nessler's reagent and incubated at room temperature 
for 10 minutes. All the measurements were done in 
triplicates by using spectrophotometer at 480 nm. Using 
the ammonium sulfate standard curve the micromoles 
of the released ammonia were determined. An amount 
of enzyme that under the specified conditions such as 
the temperature of 37°C and the pH of 8.6 is required 
to produce one micromole of the ammonia per minute 
is defined as one unit of the enzyme. According to the 
manufacturer’s instructions, a micro BCA protein assay kit 
utilized in order to determine the protein concentration. 
Finally, the results of the recombinant ASPase A1 activity 
were compared with the clinically approved E. coli 
L-asparaginase (Leunase®) activity that named ASPase E 
in this study.
Biochemical characterization of recombinant ASPase A1 
and substrate specificity assay
According to the spectroscopic method mentioned 
above, we used various concentrations of L-asparagine 
as a substrate in 50 mM Tris-HCl (pH 8.6) in order to 
determine the kinetic parameters Km and Kcat of the 
purified recombinant ASPase A1. The data were fitted to 
the Michaelis–Menten equation by nonlinear regression 
using Prism software (version 6.01, GraphPad Software 
Inc.). The Michaelis-Menten constant Km indicates the 
concentration of the substrate when the reaction rate is 
one-half of the maximal velocity (Vmax). The constant Kcat 
(catalytic rate) shows the number of substrate molecules 
turned over into the product by enzyme per second.22 In 
order to determine the effect of pH on the activity and 
stability of ASPase A1, L-asparagine hydrolysis by the 
enzyme in 50 mM Tris-HCl (pH 8.6) was considered. At 
-20, 4, 25, 37 and 50°C and by using L-asparagine in 50 
mM Tris-HCl and pH 8.6 during 120-hour incubation, 
the thermostability of ASPase A1 was investigated. In 
different intervals, samples were taken and immediately 
assayed for residual enzymatic activity by utilizing the 
L-asparagine hydrolysis. L-glutaminase activity of ASPase 
A1 was determined by 10 mM L-glutamine as a substrate 
in 50 mM Tris-HCl at 37°C and pH 8.6 using Nessler’s 
method. 
Results
Characterization of L-asparaginase sequences (ansA1 
and ansA3) from Bacillus sp. SL-1 
In this study, based on 97.0% similarity between the16S 
rDNA gene sequences of Bacillus sp. SL-1 and B. 
licheniformis (strain ATCC 14580),16 the sequences for 
L-asparaginase enzyme from the B. licheniformis were 
used as a template for designing appropriate primers for 
identifying the corresponding genes from the genome of 
the Bacillus sp. SL-1. This approach led to the amplification 
of the coding sequences of ansA1 (969 bp) and ansA3 (990 
bp) of Bacillus sp. SL-1. The DNA sequence analysis of 
the cloned ansA3(SL-1) showed the high degree of identity 
99.90% to the same gene from B. licheniformis with just a 
silent T522A substitution (Tables 1 and 2). The ansA1(SL-1) 
gene (second homologous enzyme) was also identified 
from Bacillus sp. SL-1 with 99.07% similarity to ansA1 
from B. licheniformis consists of 969 bp corresponding to 
322 residues with five nucleotide substitutions (A177T, 
C184G, G229A, C462T, A946T) leading to tow silence 
and 3 residue changes in the protein sequence (None, 
Q62 to E, D77 to N, None, I316 to L), respectively (Tables 
1 and 2). From the primary sequence alignment of 
ASPase A1 and A3, as shown in Fig. 1, it was clear that 
the identified L-asparaginases from Bacillus sp. SL-1 have 
conserved amino acids compared to the L-asparaginases 
from B. licheniformis, Bacillus sp. SL-1, B. subtilis 168, 
E. chrysanthemi and E. coli, represented in the dark blue 
columns. The primary structure of Bacillus sp. SL-1 
Table 1. Comparison of the corresponding genes for L-asparaginase enzyme from the genome of Bacillus sp. SL-1 with B. licheniformis ATCC14580, 
B. subtilis 168, E. coli K-12, and Erwinia chrysanthemi
Genes GenBank Accession numbers
Coding sequence alignment (Identity %)
B. licheniformis
ATCC
B. subtilis
168
E. coli
k-12
Erwinia 
chrysanthemi
ansA3 KX129701 99.90 72.04 44.37 42.66
ansA1 KX681674 99.48 46.35 41.99 45.20
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ASPase A3 enzyme shows high sequence identity to B. 
subtilis 168 (79.0%) and B. licheniformis (ATCC14580) 
(100.0%) L-asparaginases. ASPase A1 sequence from 
Bacillus sp. SL-1 was more similar only to L-asparaginase 
from B. licheniformis (ATCC14580) (99.21%).
 
Characterization of the produced recombinant ASPase 
A1 and A3 from Bacillus sp. SL-1
In the present study, the L-asparaginase corresponding 
genes from Bacillus sp. SL-1 were successfully cloned and 
expressed in E. coli cells (BL21 and Origami) expression 
system under aerobic condition. Using Origami expression 
system under aerobic conditions, ASPase A1 and A3 
were expressed significantly in the soluble fraction by 
the appearance of a strong band with a molecular weight 
around ∼37 kDa as shown in the SDS-PAGE analysis (Fig. 
2) corresponding to the molecular weight of L-asparaginase 
monomers from B. licheniformis and B. subtilis. The result 
of the western-blot analysis was in agreement with that of 
the SDS-PAGE experiment. The production of enzymes 
in E. coli BL21 expression system led to precipitation and 
formation of insoluble aggregates as inclusion bodies in 
cytoplasmic space. After expression of 6×His-tagged 
ansA1(SL-1) and ansA3(SL-1) L-asparaginases, the clear soluble 
fractions were subjected to the Ni Sepharose resin for 
purification (Fig. 3). The concentration of soluble purified 
L-asparaginase in Origami expression system was ~30 mg 
per one-liter bacterial culture that showed improvement 
over the produced enzyme in E. coli BL21 strain under the 
same condition.
Activity assay of recombinant ASPase A1 and ASPase A3 
from Bacillus sp. SL-1 
The preliminary hydrolytic activity assay of recombinant 
ASPase A1 and A3 from Bacillus sp. SL-1 using 
L-asparagine as substrate was showed that the identified 
Table 2. Pairwise alignment of nucleotide and amino acid sequences of L-asparaginase enzymes from Bacillus sp. SL-1 with B. licheniformis 
(ATCC14580) and analysis of their modifications
Enzymes
Protein sequence alignment
Nucleotide modification Amino acid modification Identity (%)
ASPase A3 (ansA3) T522A None 100.0
ASPase A1 (ansA1) A177T
C184G
G229A
C462T
A946T
None
Q62 to E
D77 to N
None
I316 to L
99.07
Fig. 1. Alignment of the amino acid sequence of ASPase A1 and A3 
from Bacillus sp. SL-1 with identified L-asparaginase from closely 
related microorganisms. P00805, E. coli K12; AAU41311, ASPase 
A1 B. licheniformis ATCC; AQA28589, ASPase A1 Bacillus sp. SL-
1; APT68285, ASPase A3 Bacillus sp. SL-1; AAU42953, ASPase A3 
B. licheniformis ATCC; AQR86584, B. subtilis 168; P06608, Erwinia 
chrysanthemi. Highly conserved amino acid represented in the dark 
blue columns.
Fig. 2. The SDS-PAGE and western blot analysis of 6×His-tagged 
ASPase A1. (A) SDS-PAGE analysis of samples prepared from the 
soluble fraction of cell lysate prepared from Origami transformed 
with the plasmid harboring 6×His-tagged ASPase A1 gene. Lane 1, 
immediately after induction; lane 2, 1 h after induction; lane 3, 2 h 
after induction; lane 4, 3 h after induction; lane 5, 16 h after induction 
and lane 6, protein size markers. (B) Western blot analysis of 6×His-
tagged ASPase A1 production in Origami expression system.
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ASPase A3 is completely inactive regardless of the 
presence of 6×His-tags in either N- or C-terminal of the 
target protein. However, the second homologous enzyme 
ASPase A1 from Bacillus sp. SL-1 was produced in high 
purity and characterized with excellent enzymatic activity. 
To investigate the ASPase A3 inactivity and its relationship 
with polyhistidine-tag position, the 6×His-tag was moved 
from C- terminal to N-terminal of the L-asparaginase by 
sub-cloning of the ansA3 coding sequence into pET22b 
(+). The lack of activity for ASPase A3, in either case, 
shows that the presence of 6×His-tag was not the reason 
for the observed inactivity. 
Biochemical characterization and kinetic parameters of 
recombinant ASPase A1 compared to ASPase E
The ASPase A1 expressed in Origami under aerobic 
condition was investigated for its kinetic and biochemical 
properties. As exhibited in Fig. 4, the Km value of ASPase 
A1 was almost two times higher than the determined value 
for ASPase E, while the Kcat value of 7.727 s-1 for ASPase E 
was revealed to be 3 times lower than the Kcat of 23.96s-1 
for ASPase A1 (Table 3). Purified ASPase A1 from Bacillus 
sp. SL-1 was stable in a wide range of pH values ranging 
from 4.5–10 over a period of 24 hours with maximum 
residual activity (100%). Temperature effect on enzyme 
stability and activity was studied between -20°C until 
50°C at pH 8.6 during 24 until 120 hours. As shown in 
Fig. 5, the enzyme exhibited high stability at -20°C where 
its residual activity was about 100% after one-year storage 
at this temperature. In addition, the ASPase A1 retained 
about 40% of its residual activity after 72 hours incubation 
at 37 °C. The ansA1(SL-1) L-asparaginase showed maximum 
activity (~100%) after 24 hours incubation in room 
temperature (~ 25°C). 
Discussion
To reach the main goal of the current work in developing 
the new recombinant efficient L-asparaginase with 
improved therapeutic properties, the focus of this study 
was the production of a soluble and functional enzyme 
with high-concentration and low L-glutaminase activity 
Fig. 3. The SDS-PAGE analysis of 6×His-tagged ASPase A1 prepared 
from the soluble fraction of the Origami lysate. Lane 1, purified 
ASPase A1 with the size of ~37 kDa; lane 2, protein size markers; 
lane 3, soluble fraction (total protein) of the Origami lysate for ASPase 
A1; lane 4, soluble fraction (total protein) of the Origami lysate for 
ASPase A3.
Fig. 4. Kinetic parameters analysis for ASPase A1 and ASPase E (A) 
Michaelis–Menten plot for ASPase A1 and (B) Michaelis–Menten plot 
for ASPase E.
Table 3. Kinetic properties of recombinant ASPase A1 from Bacillus sp. SL-1 in comparison with the L-asparaginase activity from other closely 
related organisms 
Source of L-Asparginase Km(µM) kcat (s-1) kcat/Km References
B. licheniformis SL-1 10.30 23.96 2.326 Present study
B. licheniformis  MTCC 429 670 - - 4
B. subtilis  B11−06 430 - - 5
E. coli k-12 5.788 7.727 1.339 Present study
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within reasonable time and cost. Recently L-asparaginase 
from B. licheniformis with low-glutaminase activity has 
been considered as a key therapeutic agent in the treatment 
of ALL.12 The glutaminase activity of L-asparaginase 
is probably related to the structural similarity between 
L-asparagine and L-glutamine amino acids although the 
latter has an extra methylene (-CH2-) group.23
In accordance to our results, previous studies have 
shown that recombinant L-asparaginase from different 
bacterial and fungal sources overexpressed in various 
strains of E. coli BL21 (DE3), E. coli BL21 (DE3) pLysS, E. 
coli JM109, E. coli BLR (DE3) can lead to different enzyme 
production profiles of soluble or insoluble forms.4, 5, 24, 25 
More recently, Saeed et al reported the overexpression of 
L-asparaginase from Aspergillus terreus in E. coli BL21 
(DE3) pLysS that precipitated in the form of amorphous 
inclusion bodies upon induction with 2 mM IPTG for 
18 h at 37°C.26 In general E. coli is considered as a proper 
host for heterologous protein production in research and 
biotechnology industry.27 However, the inability of E. coli 
to support the complex post-translational modifications 
is a serious drawback which can lead to misfolding, 
aggregation and lack of functionality of the heterologously 
expressed proteins in the cytoplasm of this expression 
system.28 Solubilizing and refolding the proteins from 
inclusion bodies is considered as a common strategy to 
resolve this problem, because of the presence of a high 
concentration of target recombinant proteins in such 
aggregates.29 However, the cost and time of the whole 
process must be considered if the goal is to produce a 
large-scale manufactured product. The soluble expression 
of recombinant proteins often leads to the production of 
properly folded, functional, and easy to purify products. 
Moreover, the refolding process of proteins from the 
aggregated inclusion bodies is not complete and can fail 
in many cases.30 Therefore, in this study, the solubility is 
considered as a key factor for the production of recombinant 
L-asparaginase in heterologous expression systems. Based 
on previous experiences regarding the expression profiles 
for the other enzymes from B. licheniformis in different E. 
coli strains, in the current study, the modified E. coli strain 
(Origami) was used to increase expression concentration 
and appropriate folding of L-asparaginase in soluble form. 
Moreover, it is noteworthy to mention that ansA1 from 
Bacillus sp. SL-1 compared to B. licheniformis ATCC 
14580 have 3 residue variations (Table 3) which may be 
the reason for the observed dissimilar expression profile. 
It has been demonstrated that such limited alterations 
only change the structure of the enzyme very slightly, 
but may still be enough to make a different subunit 
interaction of the produced recombinant proteins leading 
to aggregation.31 Due to native variations in Origami, 
which leads to its oxidative cytoplasmic environment, the 
soluble overexpression of L-asparaginases A1 and A3 have 
been facilitated leading to correct folding of the enzymes 
in this expression system.
According to the hydrolytic activity assay of recombinant 
ASPase A1 and A3, the identified ASPase A3 was 
completely inactive in the presence of 6×His-tags in either 
N- or C-terminal of the target protein. In contrast to our 
results, Sudhir et al have shown that the coding sequence 
ansA3 from another strain of B. licheniformis MTCC 429 
produces an active and stable enzyme, while the enzyme 
from ansA1 is highly unstable.4 The molecular basis 
of functional differences observed for the homologous 
enzymes is strongly related to their 3-dimensional 
structures.32 The first possibility for enzymatic inactivity of 
ASPase A3 was the 6×Histidine residue-tag in C-terminal 
of protein that may interfere with protein folding, 
oligomerization and enzyme functionality.3,33-35 However, 
this tag is present in ASPase A1and hence rules out its 
adverse effect on the activity. The more possible reason 
for the observed activity difference can be attributed to the 
high sequence difference (44% similarity) between these 
two homologs due to the sequence divergence during the 
evolution may have rendered one of the proteins inactive 
while the other preserved the activity.36
Kinetic parameters of the purified enzyme were 
measured by assessing the hydrolysis of L-asparagine 
amino acid as a substrate at different concentrations 
Fig. 5. Thermostability assessment of the recombinant ASPase A1. The residual activity of the enzyme was determined after incubation for 24, 
48, 72 and 120 hours at different temperatures.
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(Fig. 4). The ASPase A1 from Bacillus sp. SL-1 showed a 
Michaelis–Menten profile typical for such enzymes. The 
Km value of ASPase A1 was approximately 43 and 67 times 
lower than the reported value for B. subtilis B11−06 and 
B. licheniformis MTCC 429, but the value was close to 
that of B. licheniformis RAM-8 L-asparaginase as shown 
in Table 3.4,12 Interestingly, the Kcat value of ASPase A1 
was comparatively higher than the calculated value for 
therapeutical ASPase E from E.coli, which unraveled the 
high potential of the ASPase A1 for being applied in the 
therapeutical and pharmaceutical fields. 
The purified ASPase A1 from Bacillus sp. SL-1 possessed 
higher specificity for L-asparagine than L-glutamine 
amino acid similar to isolated L-asparaginase from B. 
licheniformis RAM-8 (soil isolate).12 Purified ASPase 
A1 from Bacillus sp. SL-1 was stable in wide range of 
pH values ranging from 4.5–10 over period of 24 hours 
with maximum residual activity (100%) similar to the 
reported pH range 7.0-9.0 for L-asparaginase from B. 
licheniformis RAM-8.12 L-asparaginase is one of the 
amidases that are commonly active and stable at neutral 
to alkaline pH, whereas, pH range 5.0-9.0 has also been 
reported to be optimum for amidase activity.37 The 
thermostability of ansA1(SL-1) at -20 °C was similar to the 
stability of L-asparaginase from B. licheniformis RAM-
8.12 In another study, the L-asparaginase from B. subtilis 
B11−06 retains 80% and 75% of the initial activity after 
10 h incubation at 20°C and 30°C, respectively. The 
ASPase A1 lost completely its hydrolytic activity after 
24 hours incubation at 50°C, while the L-asparaginase 
reported from B. licheniformis RAM-8 retained 20% of 
its hydrolytic activity after 24 hours incubation at 60°C.12 
These biochemical and kinetic variations are attributed 
to the genetic nature of the microbial strain sources.37 
These results indicated that the thermostability profile of 
ASPase A1 from Bacillus sp. SL-1 was almost comparable 
with L-asparaginase from B. licheniformis RAM-8, E. coli 
K12 (ASPase E) and was higher than that reported for 
L-asparaginase from B. subtilis B11−06.12
Conclusion 
In summary, the current study introduces a new and 
efficient recombinant L-asparaginase enzyme from locally 
newly isolated halo-thermotolerant Bacillus strain with 
high-level soluble overexpression in the modified E. coli 
strain (Origami). The cloning, expression and activity 
assay of recombinant ansA1 and ansA3 showed that only 
ansA1 gene produced an active and stable homologues 
enzyme with high substrate affinity toward L-asparagine. 
The concentration of soluble and functional recombinant 
L-asparaginase production was optimized in the modified 
E. coli expression system. The purified recombinant 
ASPase A1 was highly thermostable and resistant to 
the wide range of pH values. The L-glutaminase-free 
L-asparaginase activity and higher Kcat value for ASPase 
A1 from Bacillus sp. SL-1 in compared to other studied 
What is current knowledge?
√ L-asparaginase is an important anti-cancer enzyme against 
ALL.
√ Currently, Erwinia chrysanthemi and Escherichia coli 
are used in the pharmaceutical industry to production of 
L-asparaginase.
What is new here?
√ L-asparaginase enzymes from newly isolated Bacillus sp. 
SL-1 were investigated.
√ Cloned L-asparaginases were overexpressed in soluble 
form in Origami strain.
√ Only one of the two produced recombinant enzymes 
showed catalytic activity.
√ Novel active enzyme (A1) showed high Kcat value with no 
L-glutaminase activity.
√ Enzyme A1 was highly thermo-stable and resistant to wide 
range of pH values.
Research Highlights
bacterial L-asparaginases reveals the potential of this 
enzyme for pharmaceutical and industrial application.
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